Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis

被引:4
|
作者
von Gaudecker, Jane R. [1 ]
机构
[1] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA
关键词
coping; fatigue; medication adherence; multiple sclerosis; nursing; self-efficacy;
D O I
10.1097/JNN.0000000000000405
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Adherence to medication treatment in patients with multiple sclerosis (MS) is important to increase its effectiveness, reduce patient disability, prevent attacks, and increase the quality of life. Aim: This study investigated factors that influence adherence to disease-modifying therapy in patients with MS. Methods: This descriptive study was conducted with 198 patients with MS who met the inclusion criteria and agreed to participate between July 2016 and February 2017. Data were collected using an Individual Identification Form that included sociodemographic characteristics, the Multiple Sclerosis Treatment Adherence Questionnaire, the Fatigue Severity Scale, the Self-Efficacy Scale, and the Brief COPE. Results: We found that 59.6% of the patients were adherent to therapy. Patients were significantly more adherent to Avonex than other treatments, and memory problems was the most common reason for missing or forgetting medication in nonadherent patients. There was a significant difference between medication adherence and some sociodemographic characteristics and disease characteristics (P < .05). There was no significant difference between coping attitudes, fatigue, and self-efficacy level and medication adherence (P > .05). Conclusion: Patients' adherence to medication treatment was low and may be associated with social, physical, and cognitive measures.
引用
收藏
页码:302 / 302
页数:1
相关论文
共 50 条
  • [21] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [22] Multiple sclerosis disease-modifying therapy and pregnancy
    Miller, Aaron E.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : 715 - 716
  • [23] Disease-Modifying Therapy of Pediatric Multiple Sclerosis
    Tanuja Chitnis
    Neurotherapeutics, 2013, 10 : 89 - 96
  • [24] Disease-Modifying Therapy of Pediatric Multiple Sclerosis
    Chitnis, Tanuja
    NEUROTHERAPEUTICS, 2013, 10 (01) : 89 - 96
  • [25] Survey on therapy of multiple sclerosis: ACT-therapeutic adherence in patients with immunomodulatory disease-modifying therapies and factors potentially influencing treatment adherence
    Tackenberg, B.
    JOURNAL OF NEUROLOGY, 2011, 258 : 266 - 267
  • [26] A physician survey on treatment site and practice-related factors affecting adherence to disease-modifying therapies for multiple sclerosis
    Devonshire, V.
    Lapierre, Y.
    Macdonell, R.
    Tello, C. Ramo
    Patti, F.
    Fontoura, P.
    Suchet, L.
    Hyde, R.
    Balla, I.
    Kieseier, B. C.
    Frohman, E. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 274 - 274
  • [27] Improving adherence to injectable disease-modifying drugs in multiple sclerosis
    Bayas, Antonios
    EXPERT OPINION ON DRUG DELIVERY, 2013, 10 (03) : 285 - 287
  • [28] Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario Is Low
    Wong, Janice
    Gomes, Tara
    Mamdani, Muhammad
    Manno, Michael
    O'Connor, Paul W.
    NEUROLOGY, 2011, 76 (09) : A465 - A465
  • [29] Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
    Zanga, Gisela
    Drzewiscki, Estefania
    Tagliani, Paula
    Smietniansky, Maximiliano
    Rojas, Maria M. Esnaola y
    Caruso, Diego
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [30] Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low
    Wong, Janice
    Gomes, Tara
    Mamdani, Muhammad
    Manno, Michael
    O'Connor, Paul W.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2011, 38 (03) : 429 - 433